Stenzl - Figure 30
Chemotherapy induces p53 like phenotype
FIG. 30: We know from the MD Anderson classification that if p53-like tumors are exposed to neoadjuvant chemotherapy, they will alter the phenotype and they will not respond well to neoadjuvant chemotherapy.[5] Therefore those tumors would be the first upfront candidates for an alternative checkpoint inhibition-based systemic therapy.
References
[5]
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 25, 152–65 http://dx.doi.org/10.1016/j.ccr.2014.01.009
